WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search

QL ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
QL04 IMMUNOSUPPRESSANTS
QL04A IMMUNOSUPPRESSANTS
QL04AA Selective immunosuppressants
QL04AA02 muromonab-CD3
QL04AA03 antilymphocyte immunoglobulin (horse)
QL04AA04 antithymocyte immunoglobulin (rabbit)
QL04AA06 mycophenolic acid
QL04AA10 sirolimus
QL04AA13 leflunomide
QL04AA15 alefacept
QL04AA18 everolimus
QL04AA19 gusperimus
QL04AA21 efalizumab
QL04AA22 abetimus
QL04AA23 natalizumab
QL04AA24 abatacept
QL04AA25 eculizumab
QL04AA26 belimumab
QL04AA27 fingolimod
QL04AA28 belatacept
QL04AA29 tofacitinib
QL04AA31 teriflunomide
QL04AA32 apremilast
QL04AA33 vedolizumab
QL04AA34 alemtuzumab
QL04AA35 begelomab
QL04AA36 ocrelizumab
QL04AA37 baricitinib
QL04AA38 ozanimod
QL04AA39 emapalumab
QL04AA40 cladribine
QL04AA41 imlifidase
QL04AA42 siponimod
QL04AA43 ravulizumab
QL04AA44 upadacitinib
QL04AA45 filgotinib
QL04AA46 itacitinib
QL04AA47 inebilizumab

Last updated: 2021-01-27